Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Asthma is one of the most common chronic diseases of childhood. Allergen sensitization and high frequencies of comorbid allergic diseases are characteristic of severe asthma in children. Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medications. Since its initial licensing for use in adults and adolescents 12 years of age and older, the clinical efficacy, safety, and tolerability of omalizumab have been demonstrated in several published clinical trials in children aged 6 to less than 12 years with moderate-to-severe AA. These studies supported the approval of the pediatric indication (use in children aged ≥6 years) by the European Medicines Agency in 2009 and the US Food and Drug Administration in 2016. After this most recent change in licensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizumab therapy and observational studies from the past 7 years of clinical experience in Europe. Data sources were identified by using PubMed in 2016. Guidelines and management recommendations and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeting are also reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
A large-scale, consortium-based genomewide association study of asthma
Moffatt, M. F., Gut, I. G., Demenais, F., Strachan, D. P., Bouzigon, E., Heath, S., von Mutius, E., Farrall, M., Lathrop, M., & Cookson, W. O. C. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906312 · Cited by 1,818
Asthma prevalence, health care use, and mortality: United States, 2005-2009.
Akinbami, L. J., Moorman, J. E., & Liu, X. (2011) · PubMed · Cited by 946
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
Self-citationRandomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Fahy, J. V., Fleming, H. E., Wong, H. H., Liu, J. T., Su, J. Q., Reimann, J., Fick, R. B., & Boushey, H. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.6.9196082 · Cited by 713
Djukanović, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., Bao, W., Fowler-Taylor, A., Matthews, J., Busse, W. W., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200312-1651oc · Cited by 646
Self-citationTeach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.008 · Cited by 537
Self-citationTreatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Milgrom, H., Berger, W., Nayak, A., Gupta, N., Pollard, S., McAlary, M., Taylor, A. F., & Rohane, P. (2001) · Pediatrics · doi:10.1542/peds.108.2.e36 · Cited by 525
Self-citationThe anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Szefler, S. J., Mitchell, H., Sorkness, C. A., Gergen, P. J., O'Connor, G. T., Morgan, W. J., Kattan, M., Pongracic, J. A., Teach, S. J., Bloomberg, G. R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61448-8 · Cited by 458
Self-citationInternational consensus on (ICON) pediatric asthma
Papadopoulos, N. G., Arakawa, H., Carlsen, K. ‐., Custovic, A., Gern, J., Lemanske, R., Le Souef, P., Mäkelä, M., Roberts, G., Wong, G., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02865.x · Cited by 455
Self-citationFitzpatrick, A. M., Teague, W. G., Meyers, D. A., Peters, S. P., Li, X., Li, H., Wenzel, S. E., Aujla, S., Castro, M., Bacharier, L. B., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.015 · Cited by 446
Lanier, B., Bridges, T., Kulus, M., Taylor, A. F., Berhane, I., & Vidaurre, C. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.021 · Cited by 360
Self-citationSafety and tolerability of omalizumab
Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03214.x · Cited by 252
Self-citationLong, A. A., Rahmaoui, A., Rothman, K. J., Guinan, E. C., Eisner, M. D., Bradley, M. S., Iribarren, C., Chen, H., Carrigan, G. J., Rosén, K. E., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.007 · Cited by 234
Self-citationFleming, L., Murray, C., Bansal, A. T., Hashimoto, S., Bisgaard, H., Bush, A., Frey, U., Hedlin, G., Singer, F., van Aalderen, W. M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00780-2015 · Cited by 232
Self-citationOmalizumab in Asthma: An Update on Recent Developments
Humbert, M., Busse, W., Hanania, N. A., Lowe, P. J., Canvin, J., Erpenbeck, V. J., & Holgate, S. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.03.010 · Cited by 221
Self-citationChipps, B. E., Zeiger, R. S., Borish, L., Wenzel, S. E., Yegin, A., Hayden, M. L., Miller, D. P., Bleecker, E. R., Simons, F. E. R., Szefler, S. J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.014 · Cited by 203
Self-citationFeatures of severe asthma in school-age children: Atopy and increased exhaled nitric oxide
Fitzpatrick, A. M., Gaston, B. M., Erzurum, S. C., & Teague, W. G. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.08.019 · Cited by 197
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Deschildre, A., Marguet, C., Salleron, J., Pin, I., Rittié, J.-L., Derelle, J., Taam, R. A., Fayon, M., Brouard, J., Dubus, J. C., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00149812 · Cited by 194
Self-citationBerger, W., Gupta, N., McAlary, M., & Fowler-Taylor, A. (2003) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)62175-8 · Cited by 182
Severe asthma in childhood: assessed in 10 year olds in a birth cohort study
Lang, A., Carlsen, K. H., Haaland, G., Devulapalli, C. S., Munthe‐Kaas, M., Mowinckel, P., & Carlsen, K. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01672.x · Cited by 175
Pathogenesis of Allergic Airway Inflammation
Agrawal, D. K., & Shao, Z. (2009) · Current Allergy and Asthma Reports · doi:10.1007/s11882-009-0081-7 · Cited by 174
Omalizumab and the risk of malignancy: Results from a pooled analysis
Busse, W., Buhl, R., Fernandez Vidaurre, C., Blogg, M., Zhu, J., Eisner, M. D., & Canvin, J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.01.033 · Cited by 171
Self-citationTotal serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma
Borish, L., Chipps, B., Deniz, Y., Gujrathi, S., Zheng, B., & Dolan, C. M. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61221-5 · Cited by 171
Self-citationLimb, S. L., Starke, P. R., Lee, C. E., & Chowdhury, B. A. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.022 · Cited by 170
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
Stempel, D. A., Raphiou, I., Kral, K. M., Yeakey, A. M., Emmett, A. H., Prazma, C. M., Buaron, K. S., & Pascoe, S. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511049 · Cited by 169
Problematic severe asthma in children, not one problem but many: a GA2LEN initiative
Hedlin, G., Bush, A., Lødrup Carlsen, K., Wennergren, G., De Benedictis, F. M., Melén, E., Paton, J., Wilson, N., & Carlsen, K.-H. (2010) · European Respiratory Journal · doi:10.1183/09031936.00104809 · Cited by 165
Self-citationHolgate, S. T. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.052 · Cited by 163
Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma
Lemanske, R. F., Nayak, A., McAlary, M., Everhard, F., Fowler-Taylor, A., & Gupta, N. (2002) · Pediatrics · doi:10.1542/peds.110.5.e55 · Cited by 150
Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma
Covar, R. A., Leung, D. Y. M., McCormick, D., Steelman, J., Zeitler, P. S., & Spahn, J. D. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.109830 · Cited by 147
Real-life long-term omalizumab therapy in children with severe allergic asthma
Deschildre, A., Marguet, C., Langlois, C., Pin, I., Rittié, J. L., Derelle, J., Taam, R. A., Fayon, M. J., Brouard, J., Dubus, J. ‐., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00008115 · Cited by 131
Self-citationThe use of inhaled corticosteroids in pediatric asthma: update
Hossny, E. M., Rosario, N., Lee, B. W., Singh, M., El-Ghoneimy, D. H., Soh, J. Y., & Souëf, P. N. L. (2016) · World Allergy Organization Journal · doi:10.1186/s40413-016-0117-0 · Cited by 128
The oral corticosteroid-sparing effect of omalizumab in children with severe asthma
Brodlie, M., McKean, M. C., Moss, S. J., & Spencer, D. A. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-301570 · Cited by 115
Samitas, Κ., Delimpoura, V., Ζervas, Ε., & Gaga, M. (2015) · European Respiratory Review · doi:10.1183/16000617.00001715 · Cited by 109
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
Kulus, M., Hébert, J., García, E., Taylor, A. F., Vidaurre, C. F., & Blogg, M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003771338 · Cited by 102
Silkoff, P. E., Romero, F. A., Gupta, N., Townley, R. G., & Milgrom, H. (2004) · PEDIATRICS · doi:10.1542/peds.113.4.e308 · Cited by 96
Self-citationSystematic review on the use of omalizumab for the treatment of asthmatic children and adolescents
Rodrigo, G. J., & Neffen, H. E. (2015) · Pediatric Allergy and Immunology · doi:10.1111/pai.12405 · Cited by 90
Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
Milgrom, H., FowlerTaylor, A., Vidaurre, C. F., & Jayawardene, S. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.539502 · Cited by 73
Self-citationAnaphylactic reactions associated with omalizumab administration: Analysis of a case-control study
Lieberman, P. L., Umetsu, D. T., Carrigan, G. J., & Rahmaoui, A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.030 · Cited by 62
State-Based Medicaid Costs for Pediatric Asthma Emergency Department Visits
Pearson, W. S., Goates, S., Harrykissoon, S. D., & Miller, S. A. (2014) · Preventing Chronic Disease · doi:10.5888/pcd11.140139 · Cited by 60
Getting the basics right resolves most cases of uncontrolled and problematic asthma
de Groot, E. P., Kreggemeijer, W. J., & Brand, P. L. P. (2015) · Acta Paediatrica · doi:10.1111/apa.13059 · Cited by 55
Allergy, total serum immunoglobulin E, and airflow in children and adolescents in TENOR
Haselkorn, T., Szefler, S. J., Simons, F. E. R., Zeiger, R. S., Mink, D. R., Chipps, B. E., Borish, L., Wong, D. A., & for the TENOR Study Group (2010) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2010.01065.x · Cited by 53
Self-citationOmalizumab therapy is associated with reduced circulating basophil populations in asthmatic children
Hill, D. A., Siracusa, M. C., Ruymann, K., Wojno, E. D. T., Artis, D., & Spergel, J. M. (2014) · Allergy · doi:10.1111/all.12375 · Cited by 44
Faria, R., McKenna, C., & Palmer, S. (2014) · Value in Health · doi:10.1016/j.jval.2014.07.009 · Cited by 38
Xia, Y., Kelton, C. M. L., Xue, L., Guo, J. J., Bian, B., & Wigle, P. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613504124 · Cited by 28
Cited by
Advances in understanding and reducing the burden of severe asthma in children
Pijnenburg, M. W., & Fleming, L. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30399-4 · Cited by 159
Metadata
- Authors
- Chipps, B. E., Lanier, B., Milgrom, H., Deschildre, A., Hedlin, G., Szefler, S. J., Kattan, M., Kianifard, F., Ortiz, B., Haselkorn, T., Iqbal, A., Rosén, K., Trzaskoma, B., & Busse, W. W.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 139
- Issue
- 5
- Pages
- 1431-1444
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2610654869
- Cited by
- 160
- References
- 49
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.